Guggenheim began coverage on shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) in a research note issued to investors on Thursday, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $4.00 price target on the stock.
A number of other brokerages have also issued reports on EYPT. Zacks Investment Research lowered Eyepoint Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday. HC Wainwright set a $5.00 target price on Eyepoint Pharmaceuticals and gave the company a buy rating in a research report on Friday, July 12th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $4.13.
NASDAQ EYPT traded up $0.07 on Thursday, reaching $1.87. The stock had a trading volume of 926,263 shares, compared to its average volume of 392,581. The firm has a market capitalization of $196.66 million, a price-to-earnings ratio of -3.22 and a beta of 1.71. The company has a quick ratio of 5.31, a current ratio of 5.46 and a debt-to-equity ratio of 1.75. Eyepoint Pharmaceuticals has a 12-month low of $1.19 and a 12-month high of $3.94. The stock has a fifty day moving average price of $1.43 and a two-hundred day moving average price of $1.73.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The company had revenue of $7.21 million for the quarter, compared to analyst estimates of $6.75 million. Eyepoint Pharmaceuticals had a negative return on equity of 165.24% and a negative net margin of 621.04%. Sell-side analysts forecast that Eyepoint Pharmaceuticals will post -0.39 earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of the company. Essex Woodlands Management Inc. purchased a new stake in shares of Eyepoint Pharmaceuticals during the second quarter worth $68,731,000. BlackRock Inc. increased its position in shares of Eyepoint Pharmaceuticals by 298.2% during the second quarter. BlackRock Inc. now owns 4,635,930 shares of the company’s stock worth $7,602,000 after acquiring an additional 3,471,613 shares during the period. River & Mercantile Asset Management LLP purchased a new stake in shares of Eyepoint Pharmaceuticals during the second quarter worth $1,435,000. Jane Street Group LLC increased its position in shares of Eyepoint Pharmaceuticals by 1,682.6% during the second quarter. Jane Street Group LLC now owns 202,580 shares of the company’s stock worth $332,000 after acquiring an additional 191,216 shares during the period. Finally, Regal Investment Advisors LLC increased its position in shares of Eyepoint Pharmaceuticals by 176.6% during the first quarter. Regal Investment Advisors LLC now owns 193,450 shares of the company’s stock worth $346,000 after acquiring an additional 123,500 shares during the period. 58.62% of the stock is currently owned by institutional investors and hedge funds.
Eyepoint Pharmaceuticals Company Profile
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.
Featured Story: Buyback
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.